drugset
drugset / Trial / NCT01170897

Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

NCT01170897 ↗

Phase 1 Completed 27 enrolled Halozyme Therapeutics
Non-randomizedSingle-groupOpen-label

Summary

This is an open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study in patients with advanced solid tumors.

Timeline

Start
2010-07
Primary completion
2013-10
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegvorhyaluronidase Alfa Protein / enzyme biologic — —

Indications

neoplasm